Daxor Announces Oregon Health and Science University of Portland, OR Acquires BVA-100 Blood Volume Analyzer
Posted on: Monday, 24 September 2007, 12:00 CDT
Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Oregon Health and Science University, Portland, Oregon.
Oregon's Health and Science University (OHSU) is the state's only health and research university. As part of its multifaceted public mission, OHSU strives for excellence in scholarship, research, clinical practice and community service. OHSU strives to provide high-quality health care emphasizing the development and dissemination of new knowledge and cutting-edge technology.
OHSU employs 11,500 people and is Portland's largest business with an annual budget of $1.18 billion. Approximately 52% of its annual budget contributes to patient care for 447 staffed beds at OHSU Hospital and Doernbecher Children's Hospital.
In keeping with OHSU's mission to develop and disseminate cutting-edge technology, Daxor's BVA-100 Blood Volume Analyzer will be utilized to measure intravascular blood volume on critically injured patients to diagnose the blood volume status post-injury and post-operatively. Current practices associated with treatment of these types of patients currently relies on surrogate markers such as the hematocrit, heart rate, blood pressure and highly invasive procedures which measure pressures and various hemodynamic variables but do not measure a patient's intravascular blood volume. OHSU's use of the BVA-100 will quantify the improvements to patient care and patient outcomes by utilizing a direct measured blood volume provided by the BVA-100 versus the use of surrogate markers and surrogate measurements.
Daxor's Blood Volume Analyzer BVA-100 is the only FDA-approved instrument for the direct measurement of a patient's intravascular blood volume. Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.
Contact Information: Stephen Feldschuh Chief Operating Officer 212-330-8515 Email Contact Diane Meegan Investor Relations 212-330-8512 Email Contact
SOURCE: Daxor Corp.
Source: MARKET WIRE
Related Articles
- Daxor Announces a Union Hospital Purchase and a Separate Trial of Blood Volume Analyzer BVA-100
- Daxor Announces Westchester Medical Center of Valhalla, NY Purchases Blood Volume Analyzer BVA-100
- Daxor Announces St. Francis Hospital of Wilmington, DE Purchases Blood Volume Analyzer BVA-100
- Daxor Announces Publication of Clinical Study Demonstrating Blood Volume Analysis Benefits Critically Ill Surgical Patients
- Daxor Announces Virginia Commonwealth University Medical Center of Richmond, VA Acquires Blood Volume Analyzer BVA-100
- Daxor Announces Saint Luke's Hospital of Bethlehem, PA Acquires Second Blood Volume Analyzer BVA-100
- A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit
- Daxor Announces Publication of Blood Volume Research Study By Vanderbilt University and National Institutes of Health Concerning Chronic Mountain Sickness Utilizing the BVA-100 Blood Volume Analyzer
- Daxor Announces Howard University Hospital Acquires Blood Volume Analyzer BVA-100
 |
 |
User Comments (0)
RSS Feeds